Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis?
Open Access
- 2 October 2017
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 17 (1) , 660
Abstract
Group B Streptococcus (GBS) is a common commensal capable of causing severe invasive infections. Most GBS infections occur in neonates (often as pneumonia). GBS can also cause infection in adults with diabetes and other immunological impairments but rarely leads to pneumonia in adults. GBS has occasionally been found in the sputum of Cystic Fibrosis (CF) patients, an inherited condition known for progressive lung disease. However, the epidemiology and clinical significance of GBS in CF are not understood. We retrospectively reviewed a large single-centre adult CF population with an associated comprehensive, prospectively collected bacterial biobank beginning in 1978. We identified all individuals with GBS isolated from their sputum on at least one occasion. The primary outcome was risk of pulmonary exacerbation (PEx) at the time of the first GBS isolate compared to the preceding visit. Secondary outcomes included determining: prevalence of GBS infection in a CF population, whether GBS infections where transient or persistent, whether GBS strains were shared among patients, change in % predicted FEV1 at the time of GBS isolate compared to the preceding visit, PEx frequency after the first GBS isolate, change in % predicted FEV1 after the first GBS isolate, and complications of GBS infection. GBS was uncommon, infecting 3.5% (11/318) adults within our cohort. Only three individuals developed persistent GBS infection, all lasting > 12 months. There were no shared GBS strains among patients. PEx risk was not increased at initial GBS isolation (RR 5.0, CI 0.69–36.1, p=0.10). In the two years preceding initial GBS isolation compared to the two following years, there was no difference in PEx frequency (median 2, range 0–4 vs 1, range 0 to 5, respectively, p=0.42) or lung function decline, as measured by % predicted FEV1, (median −1.0%, range −19 to 7% vs median −6.0%, range −18 to 22%, p=0.86). There were no invasive GBS infections. In adults with CF, GBS is uncommon and is generally a transient colonizer of the lower airways. Despite the presence of structural lung disease and impaired innate immunity in CF, incident GBS infection did not increase PEx risk, PEx frequency, rate of lung function decline, or other adverse clinical outcomes.Keywords
This publication has 36 references indexed in Scilit:
- Macrolide and Clindamycin Resistance inStreptococcus milleriGroup Isolates from the Airways of Cystic Fibrosis PatientsAntimicrobial Agents and Chemotherapy, 2010
- The Streptococcus milleri Population of a Cystic Fibrosis Clinic Reveals Patient Specificity and Intraspecies DiversityJournal of Clinical Microbiology, 2010
- Emergence of Respiratory Streptococcus agalactiae Isolates in Cystic Fibrosis PatientsPLOS ONE, 2009
- Incidence and Clinical Presentation of Invasive Neonatal Group B Streptococcal Infections in GermanyPediatrics, 2006
- Epidemiology of Streptococcus agalactiae colonization in GermanyInternational Journal of Medical Microbiology, 2006
- Clinical and Microbiological Features ofInquilinussp. Isolates from Five Patients with Cystic FibrosisJournal of Clinical Microbiology, 2005
- Burkholderia cepaciaIs Associated with Pulmonary Hypertension and Increased Mortality among Cystic Fibrosis PatientsJournal of Clinical Microbiology, 2004
- Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic FibrosisNew England Journal of Medicine, 1994
- Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosaThe Journal of Pediatrics, 1990
- Group B Streptococcal Bacteremia in MenClinical Infectious Diseases, 1986